Pancreatic Ductal Adenocarcinoma — Trials

Pancreatic Ductal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

414 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 208
Recruiting: 129
Ph III recruiting: 13
Growth YoY: +56.5%
Industry share: 50%
Top sponsor: Revolution Medicines, Inc.
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 1–11 of 11 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05042128	The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND)	unknown	Phase 2	158	Australasian Gastro-Intestinal Trials GroupNETWORK	2	Oct 22, 2024	clinicaltrials
NCT04913337	Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies	unknown	Phase 1 / Phase 2	179	NGM Biopharmaceuticals, IncINDUSTRY